Novo Nordisk A/S
CO-AGONISTS AT GLP-1 AND GIP RECEPTORS SUITABLE FOR ORAL DELIVERY

Last updated:

Abstract:

Peptide co-agonists of the human GLP-1 and GIP receptors suitable for oral delivery, including long-acting derivatives, and their medical use in treatment and/or prevention of obesity, diabetes, and/or liver diseases are described.

Status:
Application
Type:

Utility

Filling date:

22 Jul 2021

Issue date:

9 Jun 2022